Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

NCT06637306 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Triple Negative Breast Cancer
TNBC - Triple-Negative Breast Cancer

Interventions

DRUG: Dupilumab
DRUG: Pembrolizumab
DRUG: Paclitaxel
DRUG: Carboplatin

Sponsor

Rima Patel